Back to results
US 2023/0295241 A1Published application
Artificial alphavirus-derived rna replicon expression systems
AssigneeTIBA Biotech LLC
InventorsJasdave S CHAHAL, Justine S. McPARTLAN
Life of this patent
Estimating the term…
Abstract
Synthetic alphavirus-derived replicon expression systems comprising nucleic acid sequences encoding at least one modified nonstructural protein, and synthetic nucleic acid sequences encoding at least one heterologous protein are described. Methods of producing at least one heterologous protein in a cell, or of inducing an immune response in a subject by administering and/or expressing the synthetic alphavirus-derived replicon expression systems are provided.
Claims27
A method of preventing, inhibiting, or treating the symptoms of a disease or condition in a subject comprising:
- providing a synthetic alphavirus-derived replicon nucleic acid molecule comprising:
- (i) a first nucleic acid encoding alphavirus nonstructural proteins nsP1, nsP2, nsP3, and nsP4, and comprising at least one silent mutation introduced within a region from nt 503 to nt 658, nt 658 to nt 1620, nt 1620 to nt 2560, nt 2560 to nt 3954, nt 3954 to nt 4120, nt 6381 to nt 7083, and nt 6966 to nt 7526 in the sequence of the alphavirus genome as set forth in SEQ ID NO:
- 17;
- and (ii) a second nucleic acid comprising a modified subgenomic open reading frame (ORF);
- and
- administering a therapeutically effective amount of the synthetic alphavirus-derived replicon nucleic acid molecule to a subject.
3 more elements
Dependencies are inferred from the claim text.